Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.0652W HIGH $6.80
Volume
13.91 K
Value Traded
19.11
Short % Float
0.05%
Days to Cover
1.0
+11.11%Week
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.76 M
EPS (TTM)
-6.41
P/E Ratio
-
Ent. Value
-
Total Shares
28.05 M
Float Shares
8.84 M
Insiders
0.08%
Institutions
0.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
TTOO Catalyst Timeline
Dated clinical, regulatory and corporate events for T2 Biosystems, Inc.
Past FDA Catalysts and PDUFA Decisions
How TTOO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
T2 Biosystems, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TTOO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Elsbree David BDirector | Sell | -55 23 held | $2.42 | 09/13/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in TTOO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TTOO for Q2 2026. | ||||
Ownership Trends
TTOO Short Interest
Shares sold short, counted twice a month.
0.05%
Short % of Float
of tradable shares sold short
4.9K
Shares Sold Short
0.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
14.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TTOO ranks across every disease it competes in
Competitive Position is a premium feature
See how TTOO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTTOO News
TTOOT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results Achieved record fourth quarter and full-year 2024 sepsis product revenues
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results Achieved record fourth quarter and full-year 2024 sepsis product revenues LEXINGTON, Mass., January 7, 2024 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ: TTOO) (the Company ), a leader in th
Read more →TTOOT2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens Intends to accelerate broad adoption of direct-from-whole-bloo
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create
Read more →TTOO▼ -5.1%on this news
T2 Biosystems Announces Third Quarter 2024 Financial Results Achieved 34% quarterly revenue growth compared to the prior year period
T2 Biosystems Announces Third Quarter 2024 Financial Results Achieved 34% quarterly revenue growth compared to the prior year period LEXINGTON, Mass., November 14, 2024 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTOO) (the Company ), a leader in the rapid detection of sepsis
Read more →TTOO▼ -7.4%on this news
T2 Biosystems Business Update
T2 Biosystems Business Update Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems future financial and operating results a
Read more →TTOO▼ -10.4%on this newsshared move
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results Achieved 35% increase in total revenue compared to prior year period
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results Achieved 35% increase in total revenue compared to prior year period LEXINGTON, Mass., October 7, 2024 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing
Read more →TTOOT2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union LEXINGTON, Mass., September 20, 2024 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTOO) (the Company ), a leader in the rapid detection of sepsis-cau
Read more →TTOO▼ -8.7%on this news
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients Expands available market to include over 200 children s hospitals in the United States
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients Expands available market to include over 200 children s hospitals in the United States LEXINGTON, Mass., September 16, 2024 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTOO) (the Company
Read more →TTOO▼ -9.2%on this news
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress Company plans to launch multiple direct-from-blood diagnostics over the next 15 months for antimicrobial resistance, pediatric Candida infec
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress Company plans to launch multiple direct-from-blood diagnostics over the next 15 months for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris LEXINGTON, Mass.,
Read more →TTOO▼ -6.9%on this news
T2 Biosystems Announces Second Quarter 2024 Financial Results Achieved record quarterly and first half sepsis test revenue, representing growth of 27% and 25% respectively compared to the prior year periods
T2 Biosystems Announces Second Quarter 2024 Financial Results Achieved record quarterly and first half sepsis test revenue, representing growth of 27% and 25% respectively compared to the prior year LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TT
Read more →TTOOT2 Biosystems Announces First Quarter 2024 Financial Results Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period
T2 Biosystems Announces First Quarter 2024 Financial Results Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period LEXINGTON, Mass., May 6, 2024 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTOO) (the Com
Read more →TTOOT2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance gen
Read more →TTOO▼ -10.9%on this news
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024 LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTOO) (the Company ), a leader in the
Read more →TTOO▼ -6%on this news· ran to -28% by day 3shared move
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes LEXINGTON, Mass., Marc
Read more →TTOOT2 Biosystems 4Q 2023
T2 Biosystems 4Q 2023 Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems future financial and operating results and plans
Read more →TTOOT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales LEXINGTON, Mass., February 15, 2024 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTOO) (the Comp
Read more →TTOO▲ +9.5%on this news
T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference Data demonstrates speed, accuracy, and clinical benefits of the T2Dx Instrument and T2 Biosystems sepsis panels, including encouraging early
T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference Data demonstrates speed, accuracy, and clinical benefits of the T2Dx Instrument and T2 Biosystems sepsis panels, including encouraging early detection data for T2Resistance Panel LEXINGTON, Mass., O
Read more →TTOO▼ -43.9%on this news· ran to -76% by day 3
T2 Biosystems 3Q 2023
T2 Biosystems 3Q 2023 Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems future financial and operating results and plans
Read more →TTOO▼ -43.9%on this news· ran to -76% by day 3
T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates Received FDA 510(k) clearance for the T2Biothreat Panel and significantly strengthened balance sheet
T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates Received FDA 510(k) clearance for the T2Biothreat Panel and significantly strengthened balance sheet LEXINGTON, Mass., October 12, 2023 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTO
Read more →TTOO▲ +10.5%on this news· ran to +26% by day 3
T2 Biosystems Regains Compliance with Nasdaq s Market Value of Listed Securities Requirement
T2 Biosystems Regains Compliance with Nasdaq s Market Value of Listed Securities Requirement LEXINGTON, Mass., August 9, 2023 (GLOBE NEWSWIRE) T2 Biosystems, Inc. (NASDAQ:TTOO) (the Company ), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance
Read more →TTOOT2 Biosystems Announces Second Quarter 2023 Financial Results Received FDA Breakthrough Device Designation for Candida auris test, achieved record quarterly sepsis test panel orders and received second largest sepsis dri
T2 Biosystems Announces Second Quarter 2023 Financial Results Received FDA Breakthrough Device Designation for Candida auris test, achieved record quarterly sepsis test panel orders and received second largest sepsis driven T2Dx Instrument order LEXINGTON, Mass., August 7, 202
Read more →About T2 Biosystems, Inc.
Headquarters101 Hartwell Avenue, Lexington, MA, 02421, United States
BIOPHARMAWATCH ELITE
Trade the next TTOO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime